Related Experiment Video
Updated: Mar 22, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Trial Watch-Oncolytic viruses and cancer therapy
Jonathan Pol1, Aitziber Buqué1, Fernando Aranda2
1INSERM, U1138, Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie/Paris VI, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France.
Abstract:
Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that selectively infect and kill malignant cells while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. During the past few years, great efforts have been dedicated to the development of oncolytic viruses with improved specificity and potency. Such an intense wave of investigation has culminated this year in the regulatory approval by the US Food and Drug Administration (FDA) of a genetically engineered oncolytic viral strain for use in melanoma patients. Here, we summarize recent preclinical and clinical advances in oncolytic virotherapy.
Insights
Oncolytic virotherapy uses engineered viruses to target and destroy cancer cells, stimulating an anti-tumor immune response. Recent advances led to the first FDA-approved oncolytic virus for melanoma treatment.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Oncolytic virotherapy utilizes non-pathogenic viruses to selectively eliminate malignant cells.
- This approach aims to trigger a potent anti-tumor immune response.
- Significant research has focused on enhancing viral specificity and efficacy.
Approach:
- Summarizing recent preclinical research in oncolytic virotherapy.
- Reviewing current clinical trials and outcomes.
- Highlighting the development of genetically engineered oncolytic viruses.
Key Points:
- The US Food and Drug Administration (FDA) recently approved an oncolytic virus for melanoma.
- This approval marks a significant milestone in cancer treatment.
- Ongoing research focuses on optimizing oncolytic virus platforms.
Conclusions:
- Oncolytic virotherapy represents a promising new frontier in cancer treatment.
- Continued development is crucial for expanding its therapeutic applications.
- The field is rapidly advancing, with new discoveries emerging regularly.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer